POTENTIAL TARGETS FROM HUMAN (RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES)
1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Seq.
Identity (%)		 View Dock
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		2d7t ANTI
POLYHYDROXYBUTYRATE
ANTIBODY FV, HEAVY
CHAIN
ANTI
POLYHYDROXYBUTYRATE
ANTIBODY FV, LIGHT
CHAIN
(Homo
sapiens)		5 / 12HIS H  35
VAL H  37
TRP H  50
TRP H 106
LEU L  89
None
0.64A40.39
22.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		2qyk CYCLIC AMP-SPECIFIC
PHOSPHODIESTERASE
HSPDE4A10
(Homo
sapiens)		5 / 12HIS A 445
VAL A 448
HIS A 416
PRO A 417
LEU A 431
None
1.32A22.36
20.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		3g4g CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		5 / 12HIS A 399
VAL A 402
HIS A 370
PRO A 371
LEU A 385
None
1.31A19.95
20.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		3mnz ANTI-HIV-1 ANTIBODY
13H11 HEAVY CHAIN
ANTI-HIV-1 ANTIBODY
13H11 LIGHT CHAIN
(Homo
sapiens;
Mus
musculus)		5 / 12HIS B  35
VAL B  37
TRP B  50
TRP B 103
LEU A  89
None
0.65A56.62
29.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		3mnz ANTI-HIV-1 ANTIBODY
13H11 HEAVY CHAIN
ANTI-HIV-1 ANTIBODY
13H11 LIGHT CHAIN
(Homo
sapiens;
Mus
musculus)		5 / 12HIS B  35
VAL B  37
TRP B 103
TYR A  32
LEU A  89
None
0.82A56.62
29.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		3n3z HIGH AFFINITY
CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 9A
(Homo
sapiens)		5 / 12HIS A 325
VAL A 328
HIS A 296
PRO A 297
LEU A 311
 MG  A 508 ( 4.8A)
None
None
None
None
1.42A19.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		3o57 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		5 / 12HIS A 307
VAL A 310
HIS A 278
PRO A 279
LEU A 293
None
1.33A19.82
19.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		3s35 6.64 FAB HEAVY CHAIN
(Homo
sapiens;
Mus
musculus)		5 / 12HIS H  35
VAL H  37
TRP H  50
HIS H  99
TRP H 107
None
1.13A88.94
26.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		4wzi CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		5 / 12HIS A 479
VAL A 482
HIS A 450
PRO A 451
LEU A 465
None
1.36A16.21
16.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		4xi5 FAB-94 HEAVY CHAIN
(Homo
sapiens)		5 / 12HIS D  35
VAL D  37
TRP D 111
HIS D 103
TYR D 106
None
1.35A49.38
25.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		5ohj CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		5 / 12HIS A 479
VAL A 482
HIS A 450
PRO A 451
LEU A 465
None
1.26A17.99
15.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		5u0u DH270.1 SINGLE-CHAIN
VARIABLE FRAGMENT
(Homo
sapiens)		5 / 12HIS G  35
VAL G  37
TRP G  50
TRP G 117
TYR G 111
None
1.14A39.08
25.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		5w08 K03.12 ANTIBODY
HEAVY CHAIN
(Homo
sapiens)		5 / 12HIS G  35
VAL G  37
TRP G  50
TRP G 123
TYR G 118
None
1.01Aundetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		5wb9 N60P23 FAB HEAVY
CHAIN
(Homo
sapiens)		5 / 12PHE H  33
HIS H  35
VAL H  37
TRP H  50
TRP H 110
None
0.58A23.19
15.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2xqw COMPLEMENT C3
(Homo
sapiens)		5 / 12GLN A 290
VAL A 282
TYR A 268
THR A 279
LEU A  10
None
1.29A14.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2xwb COMPLEMENT C3B
ALPHA' CHAIN
(Homo
sapiens)		5 / 12GLN B1261
VAL B1253
TYR B1239
THR B1250
LEU B 981
None
1.31A6.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3cbo HISTONE-LYSINE
N-METHYLTRANSFERASE
SETD7
(Homo
sapiens)		5 / 12GLN A 253
THR A 251
VAL A 274
ARG A 258
SER A 257
None
1.47A13.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3lh5 TIGHT JUNCTION
PROTEIN ZO-1
(Homo
sapiens)		5 / 12GLN A 796
THR A 771
THR A 770
VAL A 725
THR A 648
None
1.42A20.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		4byf UNCONVENTIONAL
MYOSIN-IC
(Homo
sapiens)		5 / 12THR A 304
VAL A 309
THR A 538
LEU A 346
SER A 275
None
1.40A9.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5dn2 NEUROPILIN-2
(Homo
sapiens)		5 / 12MET A 338
THR A 367
THR A 404
VAL A 365
TYR A 375
None
1.47A19.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1bp1 BACTERICIDAL/PERMEAB
ILITY-INCREASING
PROTEIN
(Homo
sapiens)		4 / 4PRO A 430
MET A 224
GLY A   4
VAL A   7
PC1  A 777 (-4.7A)
None
None
PC1  A 777 (-4.6A)
1.39A10.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1bp1 BACTERICIDAL/PERMEAB
ILITY-INCREASING
PROTEIN
(Homo
sapiens)		4 / 4PRO A 430
MET A 224
GLY A 226
VAL A   7
PC1  A 777 (-4.7A)
None
None
PC1  A 777 (-4.6A)
1.48A10.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1vec ATP-DEPENDENT RNA
HELICASE P54
(Homo
sapiens)		4 / 4PRO A 142
MET A 180
GLY A 182
VAL A 176
None
1.50A18.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1xcr HYPOTHETICAL PROTEIN
PTD012
(Homo
sapiens)		4 / 4PRO A 251
MET A  20
GLY A  23
VAL A 173
None
1.43A15.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2i7t CLEAVAGE AND
POLYADENYLATION
SPECIFICITY FACTOR
73 KDA SUBUNIT
(Homo
sapiens)		4 / 4PRO A 371
MET A 332
GLY A 330
VAL A 352
None
1.43A10.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2wg3 DESERT HEDGEHOG
PROTEIN N-PRODUCT
(Homo
sapiens)		4 / 4PRO A  83
MET A  99
GLY A 128
VAL A 107
None
1.33A24.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3n1q DESERT HEDGEHOG
PROTEIN
(Homo
sapiens)		4 / 4PRO B  83
MET B  99
GLY B 128
VAL B 107
None
1.37A19.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2b3o TYROSINE-PROTEIN
PHOSPHATASE,
NON-RECEPTOR TYPE 6
(Homo
sapiens)		4 / 5PRO A 426
VAL A 510
GLY A 458
VAL A 422
None
0.94A8.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2bq8 TARTRATE-RESISTANT
ACID PHOSPHATASE
TYPE 5
(Homo
sapiens)		4 / 5PRO X 114
VAL X  96
GLY X  11
VAL X  85
None
1.11A15.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2yro GALECTIN-8
(Homo
sapiens)		4 / 5PRO A  92
VAL A 114
GLY A 139
VAL A  39
None
1.09A19.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3thc BETA-GALACTOSIDASE
(Homo
sapiens)		4 / 5PRO A 513
VAL A 409
GLY A 481
VAL A 477
None
1.00A9.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		4az3 LYSOSOMAL PROTECTIVE
PROTEIN 32 KDA CHAIN
LYSOSOMAL PROTECTIVE
PROTEIN 20 KDA CHAIN
(Homo
sapiens;
Homo
sapiens)		4 / 5PRO A  11
VAL B 318
GLY A  65
VAL A  75
None
0.86A14.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		4az3 LYSOSOMAL PROTECTIVE
PROTEIN 32 KDA CHAIN
LYSOSOMAL PROTECTIVE
PROTEIN 20 KDA CHAIN
(Homo
sapiens;
Homo
sapiens)		4 / 5PRO A  11
VAL B 318
GLY A  71
VAL A  75
None
1.07A14.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		4d8o ANKYRIN-2
(Homo
sapiens)		4 / 5PRO A1420
VAL A1334
GLY A1354
VAL A1382
None
1.06A9.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		4krf PROTEIN ARGONAUTE-1
(Homo
sapiens)		4 / 5PRO A 324
VAL A 282
GLY A 193
VAL A 228
None
1.10A6.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		4mwt LYSOSOMAL PROTECTIVE
PROTEIN
(Homo
sapiens)		4 / 5PRO A  11
VAL A 318
GLY A  65
VAL A  75
PRO  A  11 ( 1.1A)
VAL  A 318 ( 0.6A)
GLY  A  65 ( 0.0A)
VAL  A  75 ( 0.6A)
0.94A10.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		4mwt LYSOSOMAL PROTECTIVE
PROTEIN
(Homo
sapiens)		4 / 5PRO A  11
VAL A 318
GLY A  71
VAL A  75
PRO  A  11 ( 1.1A)
VAL  A 318 ( 0.6A)
GLY  A  71 ( 0.0A)
VAL  A  75 ( 0.6A)
1.01A10.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5jpn COMPLEMENT C4-A
COMPLEMENT C4-A
(Homo
sapiens;
Homo
sapiens)		4 / 5PRO C1573
VAL B1403
GLY B 937
VAL C1549
None
1.06A13.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5loh SERINE/THREONINE-PRO
TEIN KINASE
GREATWALL,SERINE/THR
EONINE-PROTEIN
KINASE GREATWALL
(Homo
sapiens)		4 / 5PRO A 742
VAL A 786
GLY A 774
VAL A 766
None
0.98A13.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5vad BIFUNCTIONAL
GLUTAMATE/PROLINE--T
RNA LIGASE
(Homo
sapiens)		4 / 5PRO A1079
VAL A1125
GLY A1274
VAL A1150
None
None
PRO  A1602 (-3.7A)
None
0.99A10.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5wea PROTEIN ARGONAUTE-2
(Homo
sapiens)		4 / 5PRO A 326
VAL A 284
GLY A 195
VAL A 230
None
1.08A15.12